PropThink: Catalyst Licenses New Candidate Ahead of November Data Release
[ACN Newswire] – By Jake KingCatalyst Pharmaceutical Partners (NASDAQ:CPRX) climbed as much as 18% ahead of the bell Wednesday after the company announced that it licensed the rights to an orphan drug for Lambert-Eaton … more
View todays social media effects on CPRX
View the latest stocks trending across Twitter. Click to view dashboard